COMMUNIQUÉS West-GlobeNewswire

Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
11/06/2026
LEXINGTON, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that Alfred W. [...]
5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism
11/06/2026
– Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% response rate for the multi-component endpoint – 95% of patients completed five years of treatment COPENHAGEN, Denmark, [...]
Cosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio
11/06/2026
Doc Pharma financial profile: approximately $24 million asset base, approximately $6.7 million in average annual revenue and approximately $3.2 million in average annual gross profit. Immediately accretive: expected to [...]
LifeLabs Recognized Once Again by Forbes as One of Canada’s Best Employers for 2026
11/06/2026
Toronto, Ontario, June 11, 2026 (GLOBE NEWSWIRE) -- LifeLabs is proud to announce that we have been named as one of Canada’s Best Employers for 2026 by Forbes Canada. This award is determined by an independent survey of [...]
Treace to Present at the Sidoti Small Cap Conference
11/06/2026
PONTE VEDRA, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
Primeadine® Longevity Supplement Named Wellness Innovation of the Year in the 2026 Mindful Awards
11/06/2026
Oxford Healthspan Recognized for Bringing Spermidine and Longevity Science into the Mainstream Wellness Conversation SHERIDAN, Wyo., June 11, 2026 (GLOBE NEWSWIRE) -- Oxford Healthspan announced today that Primeadine [...]
Grant of Restricted Stock Units and Warrants to Employees in Genmab
11/06/2026
Company Announcement COPENHAGEN, Denmark; June 11, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 15,894 restricted stock units and 15,494 warrants to employees of the [...]
Priority Partners Receives Inaugural “Impact of Excellence Award”
11/06/2026
Living Word Seventh-Day Adventist Church Honors Medicaid Plan’s Commitment to Reducing Food Insecurity and Expanding Health Care Access HANOVER, Md., June 11, 2026 (GLOBE NEWSWIRE) -- Priority Partners, one of Maryland’ [...]
Human Continuum Closes Over $5 Million in Seed Round Funding to Support the Development of its Integrated Exosome-Based Therapeutic Longevity Platform
11/06/2026
Jupiter, F.L., June 11, 2026 (GLOBE NEWSWIRE) -- Human Continuum Inc. (“HC” or “the Company”) , a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced that it has closed a [...]
Ally Medical ER Opens Its Doors in Frisco
11/06/2026
Ally Medical Emergency Room is now open in one of Texas’s fastest-growing cities, bringing 24/7 five-star emergency care to Frisco families FRISCO, Texas, June 11, 2026 (GLOBE NEWSWIRE) -- Ally Medical Emergency Room [...]
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing
11/06/2026
- Acquisition of Azora and concurrent private placement positions the combined company to advance its pipeline through key clinical milestones in ulcerative colitis, including Phase 1 initiation in mid-2027 - Azora’s [...]
Novo Nordisk A/S: IT Security incident at Novo Nordisk
11/06/2026
Bagsværd, Denmark, 11 June 2026 – Novo Nordisk A/S has identified an IT security incident involving unauthorised access to a limited number of internal IT systems. Upon learning of the incident, we launched an [...]
Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK
11/06/2026
Approval is based on results from the OASIS 4 trial, which investigated semaglutide tablets 25 mg in adults living with obesity and overweight versus placebo in addition to diet and exercise Semaglutide tablets will be [...]
Applied Biologics Launches Preclinical Development Program Focused on Osteoarthritis and Other Degenerative Diseases
11/06/2026
SCOTTSDALE, Ariz., June 11, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced the [...]
Dentsply Sirona Appoints John Fortson as Chief Financial Officer
11/06/2026
Brings more than 25 years of experience leading transformation, capital deployment, and growth initiatives across global businesses CHARLOTTE, N.C., June 11, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply [...]
Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition
11/06/2026
BOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases [...]
Vivos Inc. Announces Receipt of Washington State Radioactive Materials License for IsoPet® Manufacturing
11/06/2026
Kennewick, WA, June 11, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy ™ (PRnT) for the treatment of cancerous tumors, is pleased to announce that [...]
CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer’s Disease
11/06/2026
Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer’s disease VANCOUVER, Washington, June 11, 2026 (GLOBE NEWSWIRE [...]
Imviva Biotech Presents Studies on CTD402 Allogeneic CAR-T Therapy at EHA2026 Congress
11/06/2026
Pooled Phase 1/2 data show 80% complete remission rate in pediatric R/R T-ALL/LBL patients Global TENACITY-01 study reports 86% overall response rate in adults with R/R T-ALL/LBL BOSTON, June 11, 2026 (GLOBE NEWSWIRE [...]

Pages